EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline

EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications has closed an oversubscribed USD $21.5 million (UK £15.5m) Series A financing round. The proceeds will be used to further advance the company’s microbiome drug pipeline and underpin its product development and manufacturing capabilities. The company was founded by EBS alumni Dr James McIlroy after recognising the therapeutic potential of the microbiome with the vision of building one of world’s leading microbiome drug development companies. 

Related posts

Funding for alternative to animal testing

A near-£1 million investment will help University of Dundee spinout company Ten Bio Ltd to commercialise the human skin culture system it developed to provide a viable alternative for many experiments currently performed on animals. EBS provided advice and support […]

RAB-Microfluidics secures £1.24m in funding

The team at EBS are delighted that long-term client Dr Rotimi Alabi’s company RAB-Microfluidics has secured £1.24m in an investment round led by EOS Advisory. The funding round, which also includes London-based Newable Ventures, Scottish Enterprise and existing investors, will […]